Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Neurovive Pharmaceutical AB (OTC: NEVPF).

Full DD Report for NEVPF

You must become a subscriber to view this report.


Recent News from (OTC: NEVPF)

NeuroVive receives positive FDA feedback on its NeuroSTAT TBI development plan
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ) has received positive FDA feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) at a pre-IND meeting. More news on: Neurovive Pharmaceutical AB, Healthcare stocks news, Read...
Source: SeekingAlpha
Date: September, 06 2018 07:40
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
LUND, Sweden , Sept. 6 2018 /PRNewswire/ --   NeuroVive Pharmaceutical AB   (Nasdaq Stockholm: NVP) (OTCQX: NEVPF)   today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to s...
Source: PR Newswire
Date: September, 06 2018 02:52
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
LUND, Sweden , Aug. 28, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB  (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's Hospital of Philadelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TT...
Source: PR Newswire
Date: August, 28 2018 03:00
Neurovive Pharmaceutical AB reports Q2 results
Neurovive Pharmaceutical AB ( OTCQX:NEVPF ): Q2 GAAP EPS of -SEK0.40. More news on: Neurovive Pharmaceutical AB, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 21 2018 05:54
NeuroVive Pharmaceutical AB Interim Report January - June 2018
STOCKHOLM , Aug. 21, 2018 /PRNewswire/ -- Important events January- June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalt...
Source: PR Newswire
Date: August, 21 2018 03:05
NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics
LUND, Sweden and PALO ALTO, Calif., June 18, 2018 /PRNewswire/ --  NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug c...
Source: PR Newswire
Date: June, 18 2018 02:46
NeuroVive Pharmaceutical AB Interim Report January - March 2018
STOCKHOLM , May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at a...
Source: PR Newswire
Date: May, 22 2018 02:55
NeuroVive's KL1333 shows encouraging action in early-stage study; shares up 11%
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF +10.9% ) and collaboration partner Yungjin Pharm Corp. announce positive results from a Phase 1 ascending dose clinical trial assessing mitochondrial disease candidate KL1333 in healthy volunteers. More news on: Neurovive Pharmaceutical AB, Hea...
Source: SeekingAlpha
Date: May, 21 2018 10:50
NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
LUND, Sweden and SEOUL, South Korea , May 21, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB  (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock ...
Source: PR Newswire
Date: May, 21 2018 05:18
Key events next week - healthcare
Noteworthy events during the week of May 6 - 12 for healthcare investors. More news on: Lipocine Inc., Neurovive Pharmaceutical AB, Akcea Therapeutics, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 09:51

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.192830.19610.19610.1830227,100
2018-12-070.320.3150050.320.30002300
2018-12-060.26790.3040.30850.2679400
2018-12-050.325010.310040.325010.31004200
2018-12-040.325010.310040.325010.31004200

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1027,10027,100100.0000Short
2018-12-07300300100.0000Short
2018-12-06400400100.0000Short
2018-12-04200200100.0000Short
2018-12-031,1031,103100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NEVPF.


About Neurovive Pharmaceutical AB (OTC: NEVPF)

Logo for Neurovive Pharmaceutical AB (OTC: NEVPF)

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury NeuroSTAT and one project in clinical phase I KL . The R amp D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden ticker: NVP . The share is also traded on the OTCQX Best Market in the US OTC: NEVPF .

 

Contact Information

 

 

Current Management

  • Erik Kinnman / CEO
  • Catharina Jz Johansson / CFO
  • Magnus Hansson / CMO
  • Eskil Elmer / CSO
  • Daniel Schale / Director, Comm.
  • David LaskowPooley / Executive Chairman

Current Share Structure

  • Market Cap: $20,198,911 - 03/12/2018
  • Authorized: 49,458,645 - 12/30/2015
  • Issue and Outstanding: 49,458,645 - 12/30/2015
  • Float: 17,248,125 - 12/30/2015

 


Recent Filings from (OTC: NEVPF)

Quarterly Report - NeuroVive Pharmaceutical Year End Report - January-December 2017
Filing Type: Quarterly Report - NeuroVive Pharmaceutical Year End Report - January-December 2017Filing Source: OTC Markets
Filing Date: February, 28 2018
Quarterly Report - NeuroVive Pharmaceutical Interim Report January-September 2017
Filing Type: Quarterly Report - NeuroVive Pharmaceutical Interim Report January-September 2017Filing Source: OTC Markets
Filing Date: November, 21 2017

 

 


Daily Technical Chart for (OTC: NEVPF)

Daily Technical Chart for (OTC: NEVPF)


Stay tuned for daily updates and more on (OTC: NEVPF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NEVPF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NEVPF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NEVPF and does not buy, sell, or trade any shares of NEVPF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/